KRAS and cancer: The KRAS gene, one of the most frequently mutated oncogenes in cancer, has long evaded drug targeting efforts due to the absence of effective druggable pockets on its corresponding proteins.69 In 2013, a breakthrough by a group led by Kevan Shokat reported molecules capable of covalently and selectively binding to KRASG12C mutant cysteines, reigniting hope for KRAS drug discovery.